Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:translations:polish [06.11.2018]
sallieq [Tło i naukowe uzasadnienia dla terapii]
home:translations:polish [05.10.2019] (current)
sallieq [Data]
Line 304: Line 304:
 Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu. Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu.
  
 +===== Data =====
  
 +[[home:​patients:​cohort_statistics#​later_information_2013|Success rates for various Dx, compiled in 2013]] ​
 +
 +[[home:​food:​aim_health:​aging|Olmesartan research]]
 +
 +==== Response in 5 diagnoses ====
 +
 + ​TOTALS:​ 864 members;573 report success; 119 report no success; and for 172 results are not clear.
 +
 +SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
 +
 +Sarcoidosis success 75.8%
 +
 +Chronic Fatigue Syndrome success 60.1%
 +
 +Lyme disease success 66.9%
 +
 +Rheumatoid arthritis success 69.2%
 +
 +Fibromyalgia success 64.2%
 +
 +All Other Th1 disease success 59.8% 
 ===== Notes and comments =====  ===== Notes and comments ===== 
  
home/translations/polish.1528690459.txt.gz · Last modified: 06.11.2018 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.